Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Uncover which cash back cards come with no annual fee. Choose the best option for your spending habits!
27,852 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A new Roundhill ETF is turning heads with a heavyweight position in Micron Technology. This article explains what the...
As tokens getting cheaper reshape the economics of AI, companies are ramping up budgets and expanding AI deployments,...
Utah regulators move to revoke the license of Provo Canyon School, citing a pattern of health and safety failures. Th...
As the week nears its end, Thursday often brings a fresh wave of data and earnings that can move markets. This guide ...
One year after the pledge, the Strategic Petroleum Reserve remains short of full capacity while crude prices push pas...
Account takeovers threaten every investor. This guide breaks down what customer account takeovers: what they mean for...
May delivered a powerful rally for chip stocks. This article explains why ishares semiconductor (SOXX) jumped 23% and...
Dreaming of a destination wedding? This budget-focused guide draws on the Venice-inspired celebrations around Giannin...
EDX Markets secures a $76 million Series C from SBI Holdings, marking a rare instance of a single investor backing an...
A new cross-asset note from Morgan Stanley says AI will reshape jobs rather than wipe them out, pushing workers towar...
As 2026 unfolds, inflation isn’t powered by oil alone. This report explains why something will cause inflation throug...